“The current situation has uncovered some structural weaknesses within the EU’s medicines source chain as well as a significant dependence on non-EU countries for active pharmaceutical ingredients,” Kyriakides stated. She encouraged that offer chain concerns be dealt with within an EU pharmaceutical tactic anticipated to be launched by the en